HIV-1 Genotype (RTI, PI, Integrase Inhibitors)

Clinical Significance

Identify drug resitance mutations in HIV-1 patients failing antiretroviral regimens containing RT, PR or Integrase inhibitors.
Identify transmitted drug resistance mutations in the RT, PR or integrase genes in treatment-naive patients prior to initiation of antiretroviral therapy

Specimen Requirements

3.0 mL FROZEN Plasma from 2 Lavender Top Tubes - EDTA in a Plastic Vial

Transport And Storage

24 hours Ambient
6 days Refrigerated
42 days Frozen (Transport)

Freshly drawn specimens (whole blood) may be stored at 2°C to 25°C for up to 24 hours prior to centrifugation.

Collection Instructions

 

Minimum Volume

1.2 mL Plasma

Neonatal Volume

Reference Range:

Refer to Interpretive Results

Methodology:

• Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
• Sequencing

Clinical Significance

Identify drug resitance mutations in HIV-1 patients failing antiretroviral regimens containing RT, PR or Integrase inhibitors.
Identify transmitted drug resistance mutations in the RT, PR or integrase genes in treatment-naive patients prior to initiation of antiretroviral therapy

CDM

00918060, 00918062, 00918063

CPT Coding

87900, 87901, 87906